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Abstract
Background: The National Study of HIV in Pregnancy and Childhood (NSHPC) conducts comprehensive
population-based surveillance of pregnancies in women with HIV infection in the United Kingdom/Ireland. Use of
antepartum antiretroviral therapy (ART) for prevention of mother-to-child transmission (MTCT) and to treat maternal
infection, if required, is standard practise in this population; lopinavir/ritonavir (LPV/r) is commonly used. The study
objective was to examine the use of LPV/r among pregnant women with HIV infection to describe maternal and
foetal outcomes.
Methods: The NSHPC study collected maternal, perinatal and paediatric data through confidential and voluntary
obstetric and paediatric reporting schemes. Pregnancies reported to the NSHPC by June 2013, due to deliver
2003–2012 and with LPV/r exposure were included in this analysis, using pregnancy as the unit of observation.
Results: Four thousand eight hundred sixty-four LPV/r-exposed pregnancies resulting in 4702 deliveries in 4118
women were identified. Maternal region of birth was primarily sub-Saharan Africa (77 %) or United Kingdom/Ireland
(14 %). Median maternal age at conception was 30 years. LPV/r was initiated preconception in 980 (20 %) and
postconception in 3884 (80 %) pregnancies; median duration of antepartum LPV/r exposure was 270 and 107 days,
respectively. Viral load close to delivery was <50 copies/mL in 73 % and <1000 copies/mL in 94 % of women. 63 %
of deliveries were by caesarean section (elective, 62 %; emergency, 38 %). Among singleton live births, 13 % were
<37 weeks of gestation (2.5 % <32 weeks) and 15 % had birth weight <2500 g (2.3 % <1500 g). MTCT rates were
1.1 (2003–2007) and 0.5 % (2008–2012). 134 live born children (2.9 %) had ≥1 congenital abnormality.
Conclusions: The results of this analysis using real-world data from a large number of pregnant women with HIV
infection in the United Kingdom and Ireland who received LPV/r-containing ART regimens demonstrate that these
regimens have a good safety profile and are effective for viral suppression during pregnancy, with associated low
rates of MTCT.
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Background
Initially established in 1986 to monitor paediatric pa-
tients with AIDS, the United Kingdom and Ireland’s
National Study of HIV in Pregnancy and Childhood
(NSHPC) has conducted comprehensive population-
based surveillance of HIV infection in pregnant women
since 1990. Observational data collected through the
NSHPC can be used to examine trends in the diagnosis
and management of HIV in pregnant women and related
pregnancy outcomes. Data from this and other studies
have demonstrated that vertical transmission risk reduc-
tion strategies, such as the use of antiretroviral therapy
(ART) during pregnancy, delivery management and
avoidance of breastfeeding, can result in an appreciable
reduction of the mother-to-child transmission (MTCT)
rate from approximately 20 to 0.5 % among populations
living in resource-rich settings [1–8]. In more resource-
limited regions, similarly low vertical transmission rates
have not yet been achieved, as MTCT prevention efforts
still confront numerous challenges, including access to
and availability of ART [9–11].
Guidelines issued by the British HIV Association
(BHIVA) and the World Health Organization (WHO) for
the management of HIV infection in women during preg-
nancy recommend combination ART for maternal treat-
ment needs and to reduce the risk of MTCT [12–14]. For
pregnant women with HIV infection who require ART for
their own health, based on CD4+ T-cell count or disease
stage, immediate initiation or continuation of ART is ad-
vised. National recommendations vary regarding the
timing of initiation of ART to reduce the risk of MTCT
during pregnancy in women with HIV who do not need
ART for their own health [12–15]. In the United King-
dom, current BHIVA guidelines recommend initiating
ART by 24 weeks of gestation for this group of women,
with a range of factors to be considered in deciding when
to begin therapy, including maternal CD4+ T-cell count,
baseline viral load and potential for preterm delivery [12].
As with any drug taken during pregnancy, antenatal ex-
posure to ART agents raises concerns regarding toxicity,
teratogenicity and an increased risk of adverse pregnancy
outcomes, including preterm delivery, low birth weight
and congenital abnormalities [16–19].
The incidence of pregnancy in women with HIV infec-
tion accessing HIV clinical care substantially increased
between 2000 and 2009 in the United Kingdom, and sub-
sequently stabilised. Increasing numbers of women with
HIV infection are initiating or maintaining ART during
pregnancy [3, 7, 20, 21]. Lopinavir, a protease inhibitor
that is co-formulated with ritonavir (LPV/r), is commonly
used as an anchor drug as part of an ART regimen during
pregnancy. Previous investigations into the association be-
tween the use of protease inhibitor–containing ART dur-
ing pregnancy and preterm delivery have yielded mixed
results [18, 22–28]. A 2013 systematic review of 9 studies
of ART in pregnant women with HIV infection (n=2675,
in total) found that LPV/r use was associated with reduced
maternal viral load at the time of delivery and MTCT
rates <3 %, and identified no unique safety concerns
regarding preterm delivery or low birth weight [29]. How-
ever, the majority of patients included in this analysis lived
in resource-limited regions, limiting the generalisability of
the findings to populations living in other settings.
Using data from the NSHPC for pregnancies that were
due to deliver between 2003 and 2012, the current study
examined the use of LPV/r among pregnant women with
HIV infection in the United Kingdom and Ireland to ex-
plore its association with maternal and foetal outcomes,
including viral suppression, gestational age at delivery,
prevalence of low birth weight at delivery, MTCT rates
and reported adverse infant outcomes.
Methods
The NSHPC is a population-based surveillance study of
HIV in women and children in the United Kingdom and
Ireland that collects maternal, perinatal and paediatric
data through 2 parallel, confidential and voluntary report-
ing schemes: an obstetric scheme for the notification of
pregnancies in women with HIV infection and a paediatric
scheme through which infants exposed to HIV and chil-
dren who have HIV are reported; full details are published
elsewhere [4]. Pregnancies reported through the obstetric
scheme were included in this retrospective analysis of
individual patient data if the mother was identified as
having a positive test for HIV infection by the time of de-
livery, had an expected date of delivery between 1 January
2003 and 31 December 2012 and received LPV/r at any
time during her pregnancy. LPV/r was used in approxi-
mately 37 % of all pregnancies reported to the NSHPC in
this period. Pregnancies that did not have a reported out-
come by 30 June 2013 were excluded. Pregnancy was used
as the unit of observation. HIV testing guidelines called
for polymerase chain reaction (PCR) testing shortly after
birth, and 2 weeks and 2 months after cessation of infant
prophylaxis. Antibody testing at 18 months was also
recommended.
Ethics approval
The National Study of HIV in Pregnancy and Childhood
has London Multi-Centre Research Ethics Committee
(NHS) approval (MREC/04/2/009). Individual patient con-
sent is not sought or required for reporting to the
NSHPC, which is an observational surveillance study sub-
ject to review by appropriate national information govern-
ance bodies (NIGB Ref: PIAG/BPSU 2–10(a)/2005, IG
Toolkit reference: Version 12 2014/15 EE133902-FOPHS-
PPAPPIASG; now under review with the Health Research
Authority’s Confidentiality Advisory Group). This analysis
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was based on data already collected through the routine
NSHPC study protocols and, per study approvals, individ-
ual patient consent or further permissions are not re-
quired. Furthermore, no disaggregated data were shared
with anyone outside the NSHPC, and the report is totally
anonymised.
Definitions
Maternal age was the mother’s age at conception. Trimes-
ters were defined as follows: first, <13 completed gestational
weeks; second, between 13 and 26 completed gestational
weeks; and third, ≥27 completed gestational weeks. Low in-
fant birth weight was defined as <2500 g.
Baseline CD4+ T-cell counts and viral loads (HIV RNA
measurement reported as copies/mL) were the first re-
ported measurements in the first or second trimester of
pregnancy. CD4+ T-cell counts and viral loads at delivery
were reported as the measurements taken closest to deliv-
ery during the third trimester or within 7 days after deliv-
ery. If delivery was preterm with no maternal viral load or
CD4+ T-cell count reported in the third trimester, the last
maternal measurement taken up to 28 days before and
7 days after delivery was used. Caesarean deliveries were
classified as elective if they were performed before the
initiation of labour and the rupture of membranes. A
delivery was classified as preterm if it occurred before 37
completed gestational weeks. Infant HIV infection status
was classified as uninfected or infected on the basis of
reported PCR or HIV antibody results, or indeterminate
for infants whose infection status had not yet been re-
ported. Viral suppression was defined as an HIV RNA
measurement <50 copies/mL.
Congenital abnormalities were classified according to
the WHO International Classification of Diseases, 10th
revision, using information provided by clinicians at infant
notification or at follow-up.
Statistical analysis
Statistical analysis was performed using STATA v12.0 soft-
ware (StataCorp, College Station, TX, USA), and standard
descriptive statistics were used to summarise the data,
with proportions, medians and interquartile ranges (IQRs)
presented. Comparisons were assessed using a χ2 test for
categorical variables; 95 % confidence intervals (CIs) were
calculated for rates.
Results
Baseline maternal and disease characteristics
The study population comprised 4118 women with 4864
pregnancies with LPV/r exposure, who were due to deliver
between 1 January 2003 and 31 December 2012. These
pregnancies resulted in 4759 live births (4556 singletons,
99 sets of twins, 2 single twins and 1 set of triplets), 46
stillbirths (44 singletons and 2 twins), 90 miscarriages and
72 other outcomes (terminations or left the United King-
dom/Ireland before delivery; Fig. 1). The pregnancies were
stratified by timing of LPV/r exposure, with 980 pregnan-
cies conceived whilst the woman was receiving LPV/r
therapy and 3884 pregnancies whilst LPV/r was initiated
in the antenatal period. In most cases, when LPV/r treat-
ment was initiated during pregnancy (3603/3884; 92.8 %),
women were not receiving any ART at conception; the
other 281 pregnancies were conceived on regimens that
did not contain LPV/r and a switch to LPV/r occurred
during the antenatal period. Of the 4831 pregnancies
for which nucleoside reverse transcriptase inhibitor
(NRTI) backbone therapy data were available, zidovudine
(ZDV) + lamivudine (3TC), emtricitabine (FTC) + tenofovir
(TDF), and abacavir (ABC) + 3TC were the most common,
accounting for 85 % (4106/4831) of all backbone therapy
regimens administered. When considered as a group, the
ZDV+ 3TC, FTC+TDF, or ABC + 3TC backbones were
administered more frequently in pregnancies with the initi-
ation of LPV/r (88.9 %; 3432/3862) than in pregnancies
with conception on LPV/r (69.6 %; 674/969). Of the women
with a viral load available at delivery, 73 % (2979/4083)
were suppressed overall (Table 1).
As shown in Table 1, median maternal age was 30.4 years
(range, 26.6–34.3 years); women who conceived whilst on
LPV/r were significantly older than those who began
LPV/r antenatally (P < 0.001). The majority of pregnancies
were in women who were of black African descent (3742/
4861; 77.0 %) and/or were born in sub-Saharan Africa
(3678/4810; 76.5 %). In 49.8 % of pregnancies (1934/3884)
where LPV/r was initiated during pregnancy, HIV had
already been diagnosed before conception.
CD4+ T-cell counts
Baseline CD4+ T-cell counts were available for 3593 of
4864 pregnancies (73.9 %). As shown in Table 1, the base-
line median CD4+ T-cell count of 460 cells/mm3 (IQR,
330–600 cells/mm3) among pregnancies conceived on
LPV/r was significantly higher than the median of 370
cells/mm3 (IQR, 260–520 cells/mm3) observed in preg-
nancies where LPV/r was initiated antenatally (P < 0.001).
Among women who initiated LPV/r in pregnancy, CD4+
T-cell count before initiation was available for 2503 of
3884 pregnancies (64.4 %). Median CD4+ T-cell count
was 370 cells/mm3 (IQR, 260–520 cells/mm3); 43.7 % of
these women (1093/2503) had a CD4+ T-cell count <350
cells/mm3 and 13.3 % (332/2503) had a CD4+ T-cell count
<200 cells/mm3. CD4+ T-cell counts close to delivery
were available for 3712 of 4864 pregnancies (76.3 %).
Comparing baseline and delivery CD4+ T-cell counts in
those with initiation of LPV/r in pregnancy, there was a
significant improvement, with the median increasing from
370 to 450 cells/mm3 (P < 0.001). The difference between
median CD4+ T-cell count at baseline and at delivery
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among pregnancies conceived on LPV/r was not statisti-
cally significant (P=0.13). Among all pregnancies with a
delivery CD4+ T-cell count available, approximately 40 %
(1510/3712) achieved CD4+ T-cell counts ≥500 cells/
mm3.
Viral load measurements
For 79.7 % of pregnancies (716/898) with conception on
LPV/r, a viral load measurement in the first or second
trimester was available (Table 1). In 82.0 % of these
pregnancies (587/716), the woman had an undetectable
viral load (<50 copies/mL) at baseline. A total of 95.2 %
of pregnancies (453/476) with a baseline undetectable
viral load maintained a suppressed viral load at delivery
(based on pregnancies with data available for both time
points). In pregnancies where there was a detectable
viral load in the first or second trimester, suppression
was achieved by delivery for the majority of women (84/
111; 75.7 %).
Timing and duration of LPV/r exposure
Among 4702 pregnancies resulting in a live birth or a
stillbirth, the date of initiation of LPV/r therapy was
available for 4609 pregnancies. Of these, 898 pregnancies
(19.5 %) had LPV/r exposure from before conception,
and the median duration of antenatal LPV/r exposure
was 270 days (IQR, 263–277 days). Treatment with
LPV/r was usually initiated during the second trimester
(2597/4609; 56.3 %); initiation during the first trimester
(241/4609; 5.2 %) or third trimester (873/4609; 18.9 %)
was less common. Of the 3711 women who initiated
therapy in pregnancy for whom initiation dates were
available, the median duration of antenatal LPV/r expos-
ure was 107 days (IQR, 79–132 days).
There were 3336 pregnancies with LPV/r initiated after
conception, which resulted in live births or stillbirths and
for which viral load at delivery and timing of LPV/r initi-
ation were available (Table 1). The median viral load in
this group was 5200 copies/mL (IQR, 862–22,279 copies/
mL) at baseline. By delivery, 69.0 % of women (2302/3336)
had achieved viral suppression, with most of the women
in this group beginning LPV/r treatment in the second
trimester (1731/2302; 75.2 %). In another 23.9 % of preg-
nancies (798/3336) in which LPV/r was initiated after con-
ception, a viral load of 50 to 999 copies/mL was achieved
by delivery. Among the 7.1 % of pregnancies (236/3336)
where the maternal viral load was ≥1000 copies/mL at de-
livery, the median viral load at the time of delivery was
5083 copies/mL (IQR, 1989–24,900 copies/mL); LPV/r
therapy was not initiated until the third trimester in
59.3 % of these pregnancies (140/236).
Pregnancy outcomes
A total of 95.7 % (4556/4762) of the singleton pregnancies
resulted in a live birth, whilst 98.0 % (99/101) of twin
pregnancies and a triplet pregnancy resulted in live births.
Of singleton births, 63.4 % of the infants (2877/4541) were
delivered by elective or emergency caesarean section and
36.6 % of infants (1664/4541) were delivered vaginally
(Tables 2 and 3). The median gestational age was 38 weeks
(IQR, 38–39 weeks); 12.8 % of the deliveries (585/4556)
were pre-term. Of the 101 sets of twins and 1 set of trip-
lets, 50 were delivered by elective caesarean section, 38 by
emergency caesarean section and 14 vaginally; 10 deliver-
ies were at <32 weeks gestation, and 47 were at 32–36
completed weeks. There were no significant differences in
the proportion of pre-term deliveries among singleton live
births and stillbirths according to NRTI backbone (P=0.63;
Fig. 1 Exposure to LPV/r and pregnancy outcomes in the study population. LPV/r = lopinavir/ritonavir. *Includes pregnancies (n=281; 7.2 %) that
were conceived whilst the woman was receiving a non-LPV/r-containing regimen. Shading indicates pregnancies that resulted in live births or
stillbirths (n=4702)
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Table 1 Maternal demographic and disease characteristics, stratified by timing of LPV/r exposurea
Variable AllPregnancies
(N=4864)
Pregnancies With
Conception on
LPV/r(n=980)
Pregnancies With
Initiation of LPV/r
(n=3884)
P Value
Between
Groups
N (%) or Median (IQR)
Age at conception, y 30.4(26.6–34.3) 33.3(29.8–36.6) 29.7(26.0–33.6) <0.001*
Ethnic group
White 742 (15.3) 135 (13.8) 607 (15.6) 0.07
Black African 3742 (77.0) 781 (79.7) 2961 (76.3)
Other 377 (7.8) 64 (6.5) 313 (8.1)
Missingb 3 – 3
Region of birth
United Kingdom/Ireland 663 (13.8) 114 (11.8) 549 (14.3) 0.022*
Sub-Saharan Africa 3678 (76.5) 769 (79.3) 2909 (75.8)
Elsewhere 469 (9.8) 87 (9.0) 382 (9.9)
Missingb 54 10 44
Timing of maternal HIV diagnosis
Pre-pregnancy 2914 (59.9) 980 (100) 1934 (49.8) –
During pregnancy 1950 (40.1) – 1950 (50.2)
First trimester 550 (11.3) – 550 (14.2)
Second trimester 970 (19.9) – 970 (25.0)
Third trimester 206 (4.2) – 206 (5.3)
Trimester unknown 224 (4.6) – 224 (5.8)
HIV symptoms in pregnancy
Yes 257 (5.7) 99 (11.1) 158 (4.3) –
No 4289 (94.3) 792 (88.9) 3497 (95.7)
Missingb 318 89 229
Maternal HIV risk factor
Not IDU-related 4784 (98.4) 956 (97.6) 3828 (98.6) –
IDU-related 80 (1.6) 24 (2.4) 56 (1.4)
NRTI backbone
ZDV + 3TC 3306 (68.0) 271 (27.7) 3035 (78.1) –
FTC + TDF 499 (10.3) 247 (25.2) 252 (6.5) –
ABC + 3TC 301 (6.2) 156 (15.9) 145 (3.7) –
Other 725 (14.9) 295 (30.1) 430 (11.1) –
Missing 33 (0.7) 11 (1.1) 22 (0.6) –
Baseline CD4+ T-cell count in pregnancy,c n 3593 752 2841 –
Missingb 1271 228 1043 –
Median, cells/mm3 390 (270–540) 460 (330–600) 370 (260–520) <0.001*
Pre-LPV/r initiation CD4+ T-cell count, n – N/A 2503 –
Median, cells/mm3 – N/A 370 (260–520) –
Missingb – N/A 1381 –
Delivery CD4+ T-cell count,d n 3712 688 3024 –
Median, cells/mm3 450 (320–590) 440 (330–560) 450 (310–600) –
Missingb 1152 292 860 –
Viral load at baseline,c n – 716 3336e –
Median, copies/mL – N/A 5200 (862–22,279) –
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Tables 2 and 3). The median birth weight was 3030 g (IQR,
2710–3360 g); 85.3 % of the infants (3749/4395) weighed
≥2500 g and 2.3 % of the infants (101/4395) weighed
<1500 g. For the twins and triplets, birth weight was not
provided for 7/205 infants. Excluding those for whom birth
weight was not available, 8.8 % weighed <1500 g, 46.8 %
1500–2499 g and 41 % ≥2500 g; median birth weight was
2350 g (IQR, 1930–2612 g). Fifteen percent of infants (460/
3064; live born and stillborn) weighed <2500 g in pregnan-
cies in which the mother was treated with a ZDV+ 3TC
backbone, with similar proportions for those with an FTC
+TDF backbone (14.9 %; 63/261) and an ABC+ 3TC back-
bone (13.9 %; 38/273; P=0.89); no difference by NRTI back-
bone was observed when restricting to term infants (data
not shown). For pregnancies that were delivered at term, an
infant mortality rate of 1.5 per 1000 infants (95 % CI, 0.3–
2.7) was reported. The percentage of stillbirths was similar
between pregnancies conceived on LPV/r and pregnancies
where LPV/r was initiated during pregnancy. Both the in-
fant mortality rate and the percentage of stillbirths were in-
versely correlated with gestational age. A higher percentage
of reported miscarriages or terminations were found in the
pregnancies conceived while on LPV/r (8.0 %; 76/952)
compared with pregnancies during which LPV/r therapy
was initiated (1.2 %; 44/3810).
Mother-to-child transmission rates
Data were available at the time of analysis on the HIV in-
fection status for 88.7 % of the singleton infants (4039/
4556). In the years 2008–2012, the overall MTCT rate was
0.5 % (12/2406; 95 % CI, 0.2–0.8 %), representing a >50 %
decrease from the MTCT rate in the years 2003–2007
(1.1 % [18/1633]; 95 % CI, 0.6–1.6 %). As noted in Table 4,
higher MTCT rates were associated with lower baseline
maternal CD4+ T-cell counts and later initiation of LPV/r
therapy, with MTCT rates of approximately 2 % observed
when LPV/r therapy was not initiated until the third tri-
mester, in both reporting periods. Because of reporting de-
lays due to recent birth, data on HIV infection status were
not yet available for 517 singleton infants. No infections
were reported in the twins or triplets (n=176) with known
HIV status; 27 of the twins and triplets (13 %) had an inde-
terminate infection status.
Congenital abnormality
Among the live born infants with any prenatal exposure
to LPV/r and data available (n=4609), including single-
ton and multiple births, an overall congenital abnormal-
ity rate of 2.9 % (95 % CI, 2.4–3.4 %) was observed,
based on 134 infants with an identified birth defect
(Table 5). No differences in the congenital abnormality
rate were found when the results were stratified by in-
fants who had any first-trimester exposure to LPV/r
therapy (2.9 % [32/1116]; 95 % CI, 1.9–3.8 %) or were
initially exposed during the second or third trimester
(2.9 % [97/3403]; 95 % CI, 2.3–3.4 %). In stillborn in-
fants, the overall congenital abnormality rate was 16.7 %
(6/36; 95 % CI, 3.9–29.5 %).
Among the 4645 live born and stillborn infants, the
types of congenital abnormalities most often reported
included limb reduction/additions (n=31), heart defects
(n=16), musculoskeletal defects excluding limb reduc-
tion/additions (n=15), chromosome anomalies (n=15)
and renal and urinary system defects (n=13).
Discussion
The effectiveness of LPV/r-containing regimens during
pregnancy was analysed using observational data from
comprehensive national surveillance of 4864 pregnancies
with LPV/r exposure in 4118 women with HIV infection
Table 1 Maternal demographic and disease characteristics, stratified by timing of LPV/r exposurea (Continued)
<50 copies/mL – 587 (82.0) N/A –
≥50 copies/mL – 129 (18.0) N/A –
Missing – 182 910 –
Viral load at delivery,d n – 747 3336e –
<50 copies/mL – 677 (90.6) 2302 (69.0) –
≥50–999 copies/mL – 70 (9.4) 798 (23.9) –
≥1000 copies/mL – – 236 (7.1) –
Missing – 151 910 –
Abbreviations: LPV/r lopinavir/ritonavir, IQR interquartile range, IDU injecting drug use, ZDV zidovudine, 3TC lamivudine, FTC emtricitabine, TDF tenofovir, ABC
abacavir, N/A not available
*Statistically significant, P < 0.05
aMaternal characteristics were determined on the basis of pregnancies; therefore, some women appear more than once because of repeat pregnancies reported
in the study period
bExcluded from denominator
cFirst reported measurements in the first or second trimester of pregnancy
dMeasurements reported closest to delivery in the third trimester or within 7 days of delivery. If not available, the last measurement taken up to 28 days before
and 7 days after delivery was used
ePregnancy where the outcome was a live birth or stillbirth and data were available on the timing of initiation of LPV/r and delivery viral load
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in the United Kingdom and Ireland over a 10-years
period. The results show that LPV/r-containing regi-
mens during pregnancy were effective in maintaining or
increasing maternal CD4+ T-cell counts, inducing or
maintaining suppressed maternal viral loads and sub-
stantially reducing the risk of MTCT.
The low MTCT rates and the declining trend over
time observed in this analysis are comparable with find-
ings from previous analyses of NSHPC data [3, 4, 8], in
which a steady decline in the MTCT rate over time has
been documented, from a high of 18.5 % in 1990–1993
to 1.0 % in 2003–2006, and more recently to 0.46 % in
2010–2011. Similar improvements in MTCT rates have
also been reported in other populations of women living
in resource-rich areas during similar time periods [5–7].
The declining MTCT rates across Europe partly reflect
the earlier use of ART in pregnancy among women not
on treatment at conception, together with the increasing
proportion of women who are already on suppressive
regimens at conception. In this analysis, approximately
one-fifth of pregnancies were conceived whilst the woman
was receiving LPV/r-based ART, with an undetectable
viral load in early pregnancy in 82 % of women. This is
consistent with an earlier finding from a European cohort
(women delivering in 2000–2011 in 9 Western European
countries) where 19 % of women on ART at conception
had a viral load of >200 copies/mL [30]. In the present
analysis, practically all women with an undetectable viral
load who conceived whilst on LPV/r-containing regimens
maintained viral suppression throughout the pregnancy,
whereas 69 % of women who initiated ART during preg-
nancy achieved an undetectable viral load by delivery.
In the absence of obstetric indications for a caesarean
delivery, viral suppression before the end of pregnancy
allows for a vaginal delivery [12]. In this analysis span-
ning from 2003 to 2012, slightly more than one-third of
pregnancies were delivered vaginally, despite nearly
three-quarters having an undetectable viral load by de-
livery. This finding may partly reflect the study period:
since 2005, BHIVA guidelines have included planned
vaginal delivery for women with suppressed viral load at
term as an option and have recommended this approach
since 2012 [12, 31]. However, recent findings from the
NSHPC have also shown that women with undetectable
viral loads delivering at maternity units with higher case-
loads of women with HIV infection were significantly
more likely to deliver vaginally than those delivering at
less experienced units [32]; similar regional differences
have also been observed in France [33].
Overall, nearly three-quarters of pregnancies were in
women with delivery viral load below 50 copies/mL, and
for most of the remainder, there was at least partial viral
suppression (<1000 copies/mL). In France, approxi-
mately 78 % of women with HIV infection delivering in
1997–2010 had viral loads <400 copies/mL [33], and
76 % of a Spanish cohort delivering in 2004–2007 had
an undetectable viral load (≤50 copies/mL) [5]. Factors
associated with an increased probability of having a
Table 2 Outcomes of singleton pregnancies with LPV/r
exposure (n=4762)
Total live births, n (%) 4556 (95.7)
Conception on LPV/r, n 863
Initiation of LPV/r, n 3693
Mode of delivery, n (%) n=4541
Vaginal delivery 1664 (36.6)
Elective caesarean delivery 1776 (39.1)
Emergency caesarean delivery 1101 (24.3)
Gestational age n=4556
Median (IQR), wk 38 (38–39)
<32 wk, n (%) 112 (2.5)
32–36 wk, n (%) 473 (10.4)
≥37 wk, n (%) 3971 (87.2)
Birth weight n=4395
Median (IQR), g 3030 (2710–3360)
<1500 g, n (%) 101 (2.3)
1500–2499 g, n (%) 545 (12.4)
≥2500 g, n (%) 3749 (85.3)
Infant mortality, n 24
Rate by gestational age
<32 wk, n/N, per 1000 infants
(95 % CI)
14/112, 125.0 per 1000 infants
(62.8–187.2)
32–36 wk, n/N, per 1000 infants
(95 % CI)
4/473, 8.5 per 1000 infants
(0.2–16.7)
Term, n/N, per 1000 infants
(95 % CI)
6/3971, 1.5 per 1000 infants
(0.3–2.7)
Stillbirth, n (%) 44 (0.9)
Conception on LPV/r, n/N (%) 7/952 (0.7)
Initiation of LPV/r, n/N (%) 37/3810 (1.0)
Rate by gestational age
<32 wk, n/N, per 1000 infants
(95 % CI)
23/135, 170.4 per 1000 infants
(106.1–234.6)
32–36 wk, n/N, per 1000 infants
(95 % CI)
8/481, 16.6 per 1000 infants
(5.2–28.1)
Term, n/N, per 1000 infants
(95 % CI)
13/3984, 3.3 per 1000 infants
(1.5–5.0)
Miscarriage or termination,a n (%) 120 (2.5)
Conception on LPV/r, n/N (%) 76/952 (8.0)
Initiation of LPV/r, n/N (%) 44/3810 (1.2)
Left United Kingdom/Ireland before
delivery, n (%)
42 (0.9)
Abbreviations: LPV/r lopinavir/ritonavir, IQR interquartile range
aBased on data reported from antenatal care providers
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detectable viral load at delivery in a recent European
pooled analysis included low CD4+ T-cell count (<200
cells/mm3), young maternal age, HIV diagnosis in the
third trimester or intrapartum and injection drug use
[15]. In the current analysis, among the small number of
pregnancies with higher viral loads (≥1000 copies/mL) at
delivery, ART was not initiated until the third trimester
in 60 % of women compared with 18 % in the study
population as a whole. MTCT rates were approximately
2 % for the mother-infant pairs where LPV/r therapy
was not initiated until the third trimester, with no de-
cline observed over time. Although only 14 % of
mother-infant pairs overall were in this group, they
accounted for 43 % of the MTCTs, highlighting the need
to diagnose HIV infection and initiate ART earlier in
some groups of women.
By 31 December 2014, 120 of the 517 previously indeter-
minate singletons were known to be uninfected, as well as
another 7 twins or triplets. No new infections had been
reported.
The current analysis of antenatal LPV/r exposure was
associated with a similar incidence and rate of adverse
pregnancy outcomes, including preterm delivery, low
birth weights and incidence of congenital abnormalities
as noted in other study populations. The congenital
abnormality rate (2.9 %) in this infant population with
antenatal exposure to LPV/r, regardless of overall expos-
ure time, is similar to the rates previously reported for
Table 3 Outcomes of singleton pregnancies by NRTI backbone (n = 4762)
ZDV + 3TC FTC + TDF ABC + 3TC Other/Missing P value
Preterm, n (%)
No (≥37 wk) 2762 (87.0) 380 (86.2) 249 (88.6) 565 (84.0) 0.13
Yes (<37 wk) 412 (13.0) 61 (13.8) 32 (11.4) 108 (16.0)
Gestational age, n (%)
≥37 wk 2762 (87.0) 380 (86.2) 249 (88.6) 565 (84.0) 0.31
32–36 wk 317 (10.0) 49 (11.1) 24 (8.5) 88 (13.1)
<32 wk 95 (3.0) 12 (2.7) 8 (2.9) 20 (3.0)
Low birth weight, n (%)
No (≥2500 g) 2604 (85.0) 361 (85.1) 235 (86.1) 536 (84.5) 0.95
Yes (<2500 g) 460 (15.0) 63 (14.9) 38 (13.9) 98 (15.5)
Low birth weight in term infants, n (%)
No (≥2500 g) 2492 (93.1) 340 (92.6) 226 (93.0) 502 (93.0) 0.99
Yes (<2500 g) 184 (6.9) 27 (7.4) 17 (7.0) 38 (7.0)
Abbreviations: NRTI nucleoside reverse transcriptase inhibitor, ZDV zidovudine, 3TC lamivudine, FTC emtricitabine, TDF tenofovir, ABC abacavir
Table 4 Stratified MTCT rates in singleton pregnanciesa
2003–2007 2008–2012
n/N % (95 % CI) n/N % (95 % CI)
Overall MTCT rate 18/1633 1.1 (0.6–1.6) 12/2406 0.5 (0.2–0.8)
By timing of LPV/r initiation
Before conception 2/333 0.6 (0.2–2.2) 2/635 0.3 (0.1–1.1)
First trimester 0/33 – 0/77 –
Second trimester 8/858 0.9 (0.5–1.8) 5/1397 0.4 (0.2–0.8)
Third trimester 8/376 2.1 (1.1–4.1) 5/264 1.9 (0.8–4.4)
By baseline CD4+ T-cell count
<200 cells/mm3 3/157 1.9 (0.7–5.5) 2/206 1.0 (0.3–3.5)
200–349 cells/mm3 4/340 1.2 (0.5–3.0) 1/506 0.2 (0.04–1.1)
≥350 cells/mm3 4/600 0.7 (0.3–1.7) 2/1171 0.2 (0.1–0.6)
Missing CD4+ T-cell count 7/536 1.3 (0.6–2.7) 7/523 1.3 (0.6–2.7)
Abbreviations: MTCT mother-to-child transmission, CI confidence interval, LPV/r lopinavir/ritonavir
aReported for the 4609 pregnancies where infant HIV status was available
Tookey et al. BMC Infectious Diseases  (2016) 16:65 Page 8 of 11
the entire NSHPC cohort and the uninfected general
population from the region [34, 35]. Analysis of data
from the Antiretroviral Pregnancy Registry (APR) has
also not identified any relationship between birth defects
and LPV/r use in 2458 pregnancies with exposure to
LPV/r [36]. The rate of birth defects in the APR study
population (2.2–2.4 %) was also comparable to the rate
observed in the reference population.
Some studies have indicated an association between
the use of protease inhibitor—containing ART during
pregnancy and preterm delivery, whilst others have not
[18, 22–28]. The preterm delivery rate in our study
(12.7 %) is somewhat lower than reported in some earl-
ier analyses of other European observational cohorts,
although a number of studies have noted declines in
preterm delivery rates in more recent years [15, 37];
these results may partly reflect the change in mode of
delivery policy, leading to reduction of iatrogenic late
preterm deliveries due to maternal HIV infection. The
stillbirth rate here was 9.2 per 1000 infants, which is
higher than the background rate in the United Kingdom
(5.8 per 1000 infants in 2003 and 4.7 per 1000 infants in
2013) [38, 39], but slightly lower than the previously
reported rate for the NSHPC as a whole from 1990 to
2006 (11.0 per 1000 infants) [4].
A strength of this study is that it includes data from a
large unselected population of women and children
with HIV infection collected through a long-term com-
prehensive active surveillance programme with high re-
sponse rates. A potential limitation of the study, given that
Table 5 Congenital abnormalities in live born and stillborn infants (n=4645) by LPV/r exposure timing
Overall Any first trimester
exposure to LPV/r
Earliest LPV/r exposure in
second/third trimester
Total live births (singleton +multiple), n 4609 1116 3403
Live births with ≥1 abnormality, n (%) 134a (2.9) 32 (2.9) 97 (2.9)
95 % CI 2.4–3.4 1.9–3.8 2.3–3.4
Stillbirths, n 36 8 27
Stillbirths with ≥1 abnormality, n (%) 6 (16.7) 1 (12.5) 5 (18.5)
95 % CI 3.9–29.5 – 2.9–34.2
Category of abnormality
CNS 8 3 5
Eye, ear, face and neckb 4 0 4
Cleft lip and/or palate 2 1 1
Obstructive heart defects, right 2 0 2
Obstructive heart defects, left 1 0 1
Heart—other defects 13 6 6
Respiratory systemc 3 1 2
Lower gastrointestinal system 8 2 6
Female genitalia 1 1 0
Male genitaliad 6 1 5
Renal and urinary systemc 13 2 10
Limb reduction/additione 31 5 25
Other musculoskeletal defects 15 3 12
Skin and skin derivativesf 8 2 5
Chromosome anomaly 15 4 11
Other organ systems-specified 4 1 3
Specified syndromes 3 1 1
Unspecified abnormality 3 0 3
Abbreviations: LPV/r lopinavir/ritonavir, CI confidence interval, CNS central nervous system
aIncludes 5 infants (5 live born) for whom information regarding the timing of LPV/r initiation was unavailable. None of these pregnancies were conceived
on LPV/r
b4 minor
c1 minor
d3 minor
e28 minor
f7 minor
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data are provided by antenatal care providers, is that early
miscarriages and terminations are likely to be under-
reported for women who did not receive care from an
antenatal care clinic/provider early in their pregnancy.
The difference in the proportion of miscarriages and ter-
minations reported for women conceiving whilst on LPV/
r and those initiating LPV/r in pregnancy is likely to be re-
lated to this limitation.
The low MTCT rates found in this study, which correl-
ate with MTCT rates reported in other studies, suggest
that the WHO goal of the elimination of vertical transmis-
sion of HIV in Europe [40] is achievable and within target
for populations from resource-rich areas, although coun-
tries from Eastern Europe and Central Asia face additional
barriers [9, 41]. Likewise, a review of 8 globally diverse
studies that included a large proportion of patients from
Africa noted MTCT rates of 0 to 2.8 % in women who
received LPV/r therapy during pregnancy [29].
Conclusions
Strategies for the management of HIV during pregnancy,
including earlier initiation of ART during pregnancy, are
the cornerstone for the prevention of MTCT. This analysis
shows that a large number of pregnant women with HIV
infection in the United Kingdom and Ireland have received
LPV/r-containing ART regimens, and these real-world data
demonstrate that these regimens are safe and effective for
viral suppression during pregnancy and for protecting in-
fants from perinatal HIV transmission.
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